j9

J9 is an inhibitor of Glucocorticoid resistance. J9 reverses Dexamethasone Resistance in T-cell Acute Lymphoblastic Leukemia.

Dimethylcurcumin (ASC-J9) (ASC-J9) is an androgen receptor degradation enhancer. It effectively suppresses castration-resistant prostate cancer cell proliferation and invasion.

YJ9069 is a selective CDK12/CDK13P ROTAC degrader with an IC50 of 22.22 nM in VCaP cells. Rapid degradation of CDK12/13 by this compound triggers transcription elongation defects dependent on gene length, leading to DNA damage and cell cycle arrest. YJ9069 effectively inhibits the proliferation of prostate cancer cell subpopulations and significantly suppresses prostate tumor growth in vivo.

FJ9 is a FZD7 inhibitor which disrupts protein-protein interaction between Frz7 and the PDZ domain of DVL, and induces apoptosis in melanoma cell line and non-small cell lung cancer cell line.

UAWJ9-36-3 is a SARS-CoV-2 Protease inhibitor (IC50 = 54 nM). UAWJ9-36-3 showed potent binding and enzymatic inhibition against the Mpro's from SARS-CoV-2, SARS-CoV, MERS-CoV, HCoV-OC43, HCoV-NL63, HCoV-229E, and HCoV-HKU1. UAWJ9-36-3 is a promising candidate to be further developed as a broad-spectrum coronavirus antiviral.

UAWJ9-36-1 is a SARS-CoV-2 Protease inhibitor (IC50 = 51 nM). UAWJ9-36-1 showed potent binding and enzymatic inhibition against the Mpro's from SARS-CoV-2, SARS-CoV, MERS-CoV, HCoV-OC43, HCoV-NL63, HCoV-229E, and HCoV-HKU1. UAWJ9-36-1 is a promising candidate to be further developed as a broad-spectrum coronavirus antiviral.

SJ988497 is a PROTAC JAK2 degrader that effectively inhibits proliferation in CRLF2-rearranged (CRLF2r) cells and facilitates the degradation of the CRBN neosubstrate GSPT1. Composed of a Ruxolitinib derivative, a linker, and the CRBN ligand Pomalidomide, SJ988497 is utilized in researching acute lymphoblastic leukemia (ALL) [1].

SJ995973 is a highly potent bromodomain and extraterminal (BET) protein degrader and a BET PROTAC with potential anticancer activity.

Estradiol 3-sulfamate (BLE 00084) is an orally active and highly potent steroidal estrone sulfatase (ES) inhibitor.Estradiol 3-sulfamate has a K(i) value of 73 nM for ES in human placental microsomes and can be used in the study of breast cancer.

Pradigastat (LCQ-908) is an orally active, potent and selective diacylglycerol acyltransferase 1 (DGAT1) inhibitor for the treatment of constipation, which may be used in the study of obesity and diabetes.

Zinterol is a potent and selective agonist of β2-adrenoceptor. Zinterol increases ICa in a concentration-dependent manner(EC50 of 2.2 nM).

JNJ-9676 is an orally active inhibitor of the coronavirus membrane protein, which binds to the membrane protein dimer's transmembrane domain-formed binding pocket, thereby blocking viral assembly and release. It exhibits nanomolar-level antiviral activity against the novel coronavirus and SARS-CoV.

Dimethindene maleate (SU 6518) is a histamine H1 antagonist and can be used in studies about the treatment of hypersensitivity reactions, pruritus and rhinitis.

Encainide (MJ9067), a class IC antiarrhythmic drug, holds potential for research into life-threatening and symptomatic ventricular arrhythmias as well as supraventricular arrhythmias.

Cephradine dihydrate is the hydrate form of Cephradine (free base), a semi-synthetic cephalosporin antibiotic. Cefradin inhibits the last stage of bacterial cell wall synthesis by binding to certain penicillin-binding proteins which results in cell lysis. Cell lysis is mediated by bacterial cell wall autolytic enzymes. Cefradin may interfere with autolysin inhibitors.

JNJ-9350 is a chemical compound that acts as a potent inhibitor of spermine oxidase (SMOX), demonstrated by its IC50 value of 0.01 μM, and also inhibits polyamine oxidase (PAO) with a slightly higher IC50 value of 0.79 μM, making it a potential candidate for cancer research.

Ichorcumab (JNJ-375) is a fully human IgG4 antibody that targets thrombin. It binds to exosite 1 of thrombin, inhibiting substrate binding without affecting its catalytic activity. For isotype control, refer to HumanIgG1kappa, Isotype Control.

DHFR-IN-17 (compound j9) is an orally active SaDHFR inhibitor with an IC50 value of 0.97 nM. It exhibits antibacterial activity against Staphylococcus aureus, with a minimum inhibitory concentration of 0.031 μg/mL.

Dimethylcurcumin (Standard) is a reference standard for research and analysis in studies involving Dimethylcurcumin. Dimethylcurcumin (ASC-J9) (ASC-J9) is an androgen receptor degradation enhancer. It effectively suppresses castration-resistant prostate cancer cell proliferation and invasion.